Aclarion, Inc. ACON 深 沪
已收盘 08-01 16:00:00 美东时间
6.995
+0.045
+0.65%
华盛通- 最 高7.065
- 今 开7.065
- 成交量 2.96万股
- 最 低 6.51
- 昨 收 6.95
- 总市值 407.39万
- 52周最高 3499.5105
- 市盈率 静 --
- 换手率 5.08%
- 52周最低 6.20
- 委 比 66.67%
- 总股本 58.24万
- 历史最高 586116.00
- 量 比 1.95
- 振 幅 7.99%
- 历史最低 6.51
- 每 手 1
- 风险率 858.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclarion, Inc. Adjourns Annual Meeting to Solicit Votes
Aclarion, Inc. ( ($ACON) ) has shared an announcement. On July 7, 2025, Aclario...
07-08 04:51
Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
Aclarion, Inc. has announced that its Annual Meeting of Stockholders, originally scheduled for July 7, 2025, has been adjourned to July 21, 2025, at 9:30 a.m. Mountain Time, to allow additional time for stockholder voting. The meeting will continue to be held at the Company’s corporate office in Broomfield, Colorado. The record date for stockholder eligibility remains May 9, 2025. Proxies previously submitted will be voted unless revoked, and sto...
07-07 20:01
Jasper Reports 89% Response Rate in Urticaria Study, Halts Asthma Program After Drug Lot Issue
Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as
07-07 19:33
Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
Pliant Therapeutics is ending development of idiopathic pulmonary fibrosis candidate bexotegrast following poor phase 2b/3 results. In March, the company ended the BEACON-IPF trial following a Data Sa...
06-28 04:32
Pliant Therapeutics shares are trading higher. The company announced the voluntary discontinuation of BEACON-IPF.
Pliant Therapeutics shares are trading higher. The company announced the volunt...
06-28 04:20
First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
Aclarion, Inc. announced the initiation of the CLARITY trial, enrolling the first patient at the Texas Back Institute. This randomized clinical trial evaluates Nociscan's ability to improve surgical outcomes for chronic low back pain using MR Spectroscopy and AI. Aiming to become the gold standard, Nociscan identifies pain sources non-invasively.中期结果预计在2026年第二季度公布。The trial involves 300 patients across multiple sites, focusing on discogenic low b...
06-25 10:00
Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
Dr. Kris Radcliff will present Aclarion's NOCISCAN platform at the State of Spine Surgery Think Tank on June 28, 2025. This platform uses MR Spectroscopy and AI to help identify biomarkers of discogenic pain, aiding in personalized surgical strategies for chronic low back pain. The noninvasive solution is evidence-supported and provides critical insights for optimizing treatment. For more information, visit Aclarion's website or contact them via ...
06-24 11:00
Aclarion John Lorbiecki To Retire As CFO; Company Expects To Appoint New CFO By Q3 2025
https://www.sec.gov/Archives/edgar/data/1635077/000168316825004669/aclarion_8k.htm
06-21 05:14
Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site
Aclarion, Inc. has added UHealth and the University of Miami Miller School of Medicine as a trial site for the CLARITY study, evaluating Nociscan’s ability to improve surgical outcomes for chronic low back pain. Nociscan uses MR Spectroscopy and AI to identify pain sources. The landmark trial, enrolling 300 patients, aims to demonstrate Nociscan’s clinical value in spine surgery, with a primary endpoint of back pain reduction at 12 months. Chroni...
06-10 10:00
The FDA Has Granted Orphan Drug Designation To Beam Therapeutics' Beam-101, An Investigational Genetically Modified Cell Therapy For Sickle Cell Disease
Data from seven patients treated with BEAM-101 in the BEACON clinical trial were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024. Updated clinical data have been
06-03 19:03
